The China Food and Drug Administration has announced the suspension of its electronic pharmaceutical products monitoring system run by Alibaba Health Information Technology while the it drafts amendments to regulations on the monitoring of drug sales in China, Reuters reported, citing a statement published to the regulator’s website. The regulator said it would seek comments on the changes until March 23. Hunan-based pharmacy chain Yontinhe Group said in January it was suing the administration over the online monitoring system on the grounds it provided the Alibaba affiliate – which owns its own online drug sales firm – with an unfair advantage.
You must log in to post a comment.
Yes, I would like to receive emails from China Economic Review. (You can unsubscribe anytime)
Copyright © 2018 SinoMedia Group Limited All rights reserved